Clinical trials: Stage II Bladder Cancer
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 747 sites in United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Rectal Cancer
The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study
Radiotherapy has a significant impact on local control, disease free survival and overall survival in patients with rectal cancer T2, N1, M0 and T3-4, any N, M0.
- Trial name
- NCT01142713
- Testing
- Patient Position During Radiotherapy
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Urinary Bladder Neoplasms
Irreversible Electroporation(IRE) For Unresectable Urinary Bladder Neoplasms
The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Urinary Bladder Neoplasms.
- Trial name
- IRE (NCT02430623)
- Testing
- Irreversible electroporation (IRE), NanoKnife
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Bladder Cancer, Kidney Cancer
Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants
RATIONALE: Studying samples of blood and urine from patients with cancer and from healthy participants in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Bladder Cancer, Kidney Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00900276
- Testing
- immunologic technique, laboratory biomarker analysis, mass spectrometry
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II
Addressing Barriers to Palliative Care Use in Bladder Cancer
Investigators plan to establish an in-depth understanding of knowledge and beliefs about palliative care in advanced Bladder Cancer patients and their caregivers, and to identify factors associated with positive and negative…
- Conditions
- Muscle-Invasive Bladder Carcinoma, Bladder Cancer Stage II, Bladder Cancer Stage III, Bladder Cancer Stage IV
- Trial name
- NCT04598724
- Testing
- Surveys
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
Paclitaxel-binding Albumin and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
This is a phase II study of Paclitaxel-binding albumin, Cisplatin as neoadjuvant chemotherapy in patients with muscle-invasive urothelial carcinoma of the bladder.
- Trial name
- NCT04060459
- Testing
- Paclitaxel-binding albumin
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Third Military Medical University
Bladder Cancer
The Difference of Two Year Recurrence Rate According to Anesthetic Method During Transurethral Resection of Bladder Mass in Patients With Non-muscle Invasive Bladder Cancer: Prospective, Randomized, Clinical Phase II Study
The investigators compare the recurrence rate difference between two years after transurethral resection of the bladder tumor according to the method of anesthesia. Anesthetic methods are general anesthesia and spinal anesthesia.
- Trial name
- NCT03597087
- Testing
- Anesthesia before transurethral resection of the bladder tumor, Anesthesia
- Where
- South Korea
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
No Evidence of Disease, Stage II Bladder Cancer
MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer
This pilot research trial studies how well myeloid derived suppressor cells (MDSC) clinical assay works in finding and monitoring cancer cells in blood and urine samples from patients with or without localized or metastatic…
- Conditions
- No Evidence of Disease, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IVA Bladder Cancer
- Trial name
- NCT02735512
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Bladder Cancer
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
Neoadjuvant chemotherapy plus radical cystectomy is the standard if care for cisplatin-eligible patients with MIBC. Developments in the last two decades suggest that bladder sparing therapy may be a valuable alternative to…
- Trial name
- NCT05531123
- Testing
- Tislelizumab, gemcitabine and cisplatin, Modified hypofractionation
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fudan University
Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
This randomized clinical trial studies the Family Caregiver Palliative Care Intervention in supporting caregivers of patients with stage II-IV gastrointestinal, gynecologic, urologic and lung cancers.
- Conditions
- Healthy Subject, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Psychosocial Effects of Cancer and Its Treatment
- Trial name
- NCT01846520
- Testing
- educational intervention, telephone-based intervention, quality-of-life assessment
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Urinary Bladder Neoplasms
Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer
Gemcitabine and cisplatin represent the standard first-line chemotherapy in metastatic bladder carcinoma. This regimen has replaced in most centers the MVAC combination showing a similar efficacy but less toxicity.
- Trial name
- NCT00818350
- Testing
- SUNITINIB
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Campania Younger Oncologists Association
Urology
Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in Her2-expressing Muscle-invasive Bladder Cancer: A Phase II, Open-Label, Randomized Clinical Trial
This study aims to evaluate the efficacy of disitamab vedotin combined with toripalimab as a bladder-preserving treatment combination in patients with HER2 positive locally advanced MIBC, including one year bladder-intact DFS…
- Trial name
- NCT07151560
- Testing
- 6 cycle RC48 and JS001, 12 cycle RC48 and JS001
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Renmin Hospital of Wuhan University
Stage II Gallbladder Cancer, Stage IIIA Gallbladder Cancer
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
This phase II trial is studying how well giving 3-AP together with gemcitabine works in treating patients with unresectable or metastatic bile duct or gallbladder cancer.
- Conditions
- Stage II Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IVA Gallbladder Cancer
- Trial name
- NCT00075504
- Testing
- triapine, gemcitabine
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)